LB Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +64.1% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 19.2% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation F
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 38.3x | Better than 14% |
| P/E vs own 5-yr range | 99th pctl | Better than 4% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -24.4% | Better than 15% |
| Return on invested capital | -27.2% | Better than 11% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -18.4% | Better than 33% |
| 6-month return | 38.2% | Better than 92% |
| 12-month return (ex latest month) | 152.6% | Better than 98% |
| Distance below 52-week high | 22.5% | Better than 55% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 41.4x | Better than 99% |
| Debt to assets | 1.1% | Better than 92% |
| Interest coverage | -0.3x | Better than 23% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 69.6% | Better than 76% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 40.04
- Open
- 39.53
- Day range
- 38.57 - 40.67
- Avg price
- 38.97
- Volume
- 303.06K
- Turnover
- 11.81M
- Turnover ratei
- 1.15%
- Volume ratioi
- 0.73
- Amplitudei
- 5.25%
- 52-week rangei
- 15.55 - 50.16
Valuation
- P/Ei
- -39.01
- P/E (TTM)i
- 38.31
- P/Bi
- 3.01
- EPSi
- -1.00
- Book value / shi
- 12.91
- Net profit
- -32.23M
- Net assets
- 417.65M
Share structure
- Market cap
- 1.26B
- Float capi
- 1.03B
- Shares out
- 32.36M
- Float sharesi
- 26.46M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2025-09-11
22.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+1.35M net over the window
Short interest
- Shares short
- 6.20M
- % of floati
- 19.22%
- Days to coveri
- 17.98
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of LB Pharmaceuticals (LBRX)?
LB Pharmaceuticals last traded at 38.85. This page shows a periodic quote snapshot. Check the displayed quote time.
What is LB Pharmaceuticals's market cap?
About 1.26B.
What is the P/E ratio of LB Pharmaceuticals?
The trailing twelve-month P/E is 38.31. The Valuation tab shows it against the stock's own five-year range.
Does LB Pharmaceuticals pay a dividend?
LB Pharmaceuticals does not currently pay a regular dividend.
Is LB Pharmaceuticals a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 65.88, which implies 69.6% upside from the current price. This is not investment advice.
What is LB Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates LB Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.
LB Pharmaceuticals discussion 0 comments